ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
Dow Jones
42.063,36
0,09%
Euro vs US Dollar
1,11705
-0,04%
Bitcoin
63.079,41
-0,20%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) News

SAN

Sanofi (SAN)

Sanofi
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:SAN
DatumZeitQuelleÜberschriftSymbolFirma
21/09/202400h36GlobeNewswire Inc.Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantEU:SANSanofi
20/09/202413h45GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldEU:SANSanofi
20/09/202411h30GlobeNewswire Inc.Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyEU:SANSanofi
13/09/202418h15GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)EU:SANSanofi
12/09/202407h00GlobeNewswire Inc.Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersEU:SANSanofi
02/09/202407h00GlobeNewswire Inc.Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosisEU:SANSanofi
08/08/202407h00GlobeNewswire Inc.Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantEU:SANSanofi
25/07/202416h56GlobeNewswire Inc.Press Release: Online availability of Sanofi’s half-year financial report for 2024EU:SANSanofi
25/07/202407h30GlobeNewswire Inc.Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedEU:SANSanofi
17/07/202423h27GlobeNewswire Inc.Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AEU:SANSanofi
03/07/202407h00GlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
03/07/202407h00GlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
03/07/202407h00GlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneEU:SANSanofi
26/06/202423h30GlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
26/06/202423h30GlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
26/06/202423h30GlobeNewswire Inc.Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ansEU:SANSanofi
25/06/202419h32GlobeNewswire Inc.Press Release: Availability of the Q2 2024 Aide-mémoireEU:SANSanofi
25/06/202419h32GlobeNewswire Inc.Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »EU:SANSanofi
21/06/202409h30GlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
21/06/202409h30GlobeNewswire Inc.Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de SanofiEU:SANSanofi
21/06/202409h30GlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
21/06/202407h00GlobeNewswire Inc.Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilieEU:SANSanofi
21/06/202407h00GlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
21/06/202407h00GlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
20/06/202414h00GlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
20/06/202414h00GlobeNewswire Inc.Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en AfriqueEU:SANSanofi
20/06/202414h00GlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
12/06/202420h19GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024EU:SANSanofi
12/06/202420h19GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2024EU:SANSanofi
03/06/202422h15GlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Kürzlich von Ihnen besucht

NYSE
KMB.WI
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten